Collaboration and License Agreements - Summarizes the Deferred Revenue Amounts Allocated to Performance Obligations (Details) - USD ($) $ in Thousands |
Dec. 31, 2025 |
Dec. 31, 2024 |
|---|---|---|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Deferred revenue, net of current | $ 111,332 | $ 16,147 |
| Roche Agreement [Member] | ||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Deferred revenue, net of current | 22,657 | 25,017 |
| Roche Agreement [Member] | Research and Development of Initial Targets [Member] | ||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Deferred revenue, net of current | 14,140 | 19,395 |
| Roche Agreement [Member] | Research and Development for Replacement Targets [Member] | ||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||
| Deferred revenue, net of current | $ 8,517 | $ 5,622 |